Trial reportThe Journal of infectious diseases2018
Protection of the Human Gut Microbiome From Antibiotics.
Trial report in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influence of the Administration of DAV132 7.5g Tid for 7 Days on the Fecal Levels of Moxifloxacin During and After a 5-day Oral Treatment With Moxifloxacin 400mg Oad in Healthy Volunteers
A European Multicenter, Randomized, Parallel-group Study to Evaluate the Safety and Efficacy/Performance of DAV132 in Hospitalized Patients at High Risk for Clostridium Difficile Infection and Who Receive Fluoroquinolones for the Treatment of Acute Infections
Who cites it
86 citing papers in PubMed, 161 citations in OpenAlex.
- The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers.Nature communications · 2024Trial
- An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.The Journal of antimicrobial chemotherapy · 2022Trial
- Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity.Antimicrobial agents and chemotherapy · 2019Trial
- Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.Antimicrobial agents and chemotherapy · 2019Trial
- The Cost of the Cure: Antibiotic Exposure as a Risk Factor for Irritable Bowel Syndrome.Antibiotics (Basel, Switzerland) · 2026Review
- Antibiotic Class-Specific Effects on Inflammatory Bowel Disease: Microbiome Disruption, Risk, and Recovery.International journal of molecular sciences · 2026Review
- Changes in the Gut Microbiome Following Perioperative Prophylactic Cefazolin Administration in Patients Undergoing Orthopedic Surgery: A Longitudinal Prospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Antibiotic-induced gut microbiome dysbiosis: risks and strategies for mitigation.The EMBO journal · 2026Review
- Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals.Nature medicine · 2026Article
- Mapping 25 years of research on gut microbiota and antibiotic resistance: bibliometric insights and future directions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Effects of commonly used antibiotics on children's developing gut microbiomes and resistomes in peri-urban Lima, Peru.The Journal of antimicrobial chemotherapy · 2025Article
- A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity.Gut microbes · 2025Article
- Opportunistic intestinal parasitic infections and associated factors among patients living with HIV/AIDS attending antiretroviral therapy in the Central Ethiopia Regional State: a multi-center analytical cross-sectional study.BMC infectious diseases · 2025Article
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- Lactoperoxidase: Properties, Functions, and Potential Applications.International journal of molecular sciences · 2025Review
- The effects of repeated fecal transplantation and activated charcoal treatment on gut dysbiosis induced by concurrent ceftriaxone administration in mice.Scientific reports · 2025Article
- Gut integrity in intensive care: alterations in host permeability and the microbiome as potential therapeutic targets.Journal of intensive care · 2025Review
- Antibiotic-perturbed microbiota and the role of probiotics.Nature reviews. Gastroenterology & hepatology · 2025Review
- Gut Microecological Prescription: A Novel Approach to Regulating Intestinal Micro-Ecological Balance.International journal of general medicine · 2025Review
- Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier.Research (Washington, D.C.) · 2025Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibiotics are life-saving drugs but severely affect the gut microbiome with short-term consequences including diarrhea and selection of antibiotic-resistant bacteria. Long-term links to allergy and obesity are also suggested. We devised a product, DAV132, and previously showed its ability to deliver a powerful adsorbent, activated charcoal, in the late ileum of human volunteers. Methods: We performed a randomized controlled trial in 28 human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic moxifloxacin in 2 parallel groups, with or without DAV132 coadministration. Two control goups of 8 volunteers each receiving DAV132 alone, or a nonactive substitute, were added. Results: The coadministration of DAV132 decreased free moxifloxacin fecal concentrations by 99%, while plasmatic levels were unaffected. Shotgun quantitative metagenomics showed that the richness and composition of the intestinal microbiota were largely preserved in subjects co-treated with DAV132 in addition to moxifloxacin. No adverse effect was observed. In addition, DAV132 efficiently adsorbed a wide range of clinically relevant antibiotics ex vivo. Conclusions: DAV132 was highly effective to protect the gut microbiome of moxifloxacin-treated healthy volunteers and may constitute a clinical breakthrough by preventing adverse health consequences of a wide range of antibiotic treatments. Clinical Trials Registration: NCT02176005.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.